<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 22, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00060138</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU-080235</org_study_id>
    <secondary_id>CDR0000299530</secondary_id>
    <secondary_id>CBI-1102</secondary_id>
    <secondary_id>CBI-CAL-03</secondary_id>
    <nct_id>NCT00060138</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases</brief_title>
  <official_title>A Phase I-II, 24-Week, Multi-Center, Double-Blind, Randomized, Dose-Ranging Study To Evaluate The Safety And Efficacy Of A Humanized Monoclonal Antibody To PTHrP Versus Zoledronic Acid In Patients With Breast Cancer Metastatic To Bone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Chugai Pharmaceutical</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver&#xD;
      tumor-killing substances to them without harming normal cells. Zoledronate may prevent bone&#xD;
      loss and stop the growth of tumor cells in bone. It is not yet known whether monoclonal&#xD;
      antibody is more effective than zoledronate in treating women who have breast cancer and bone&#xD;
      metastases.&#xD;
&#xD;
      PURPOSE: Randomized phase I/II trial to compare the effectiveness of monoclonal antibody with&#xD;
      that of zoledronate in treating women who have breast cancer and bone metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the safety and tolerability of monoclonal antibody CAL vs zoledronate in women&#xD;
           with breast cancer and bone metastases.&#xD;
&#xD;
        -  Compare, preliminarily, the potential effects of these drugs on skeletal&#xD;
           events/manifestations related to bone metastases, including hypercalcemia, bone pain,&#xD;
           bone metastatic lesions, complications (e.g., pathologic fracture and spinal cord&#xD;
           compression), and interventions (e.g., surgery and radiotherapy) in these patients.&#xD;
&#xD;
        -  Compare changes in ECOG performance status in patients treated with these drugs.&#xD;
&#xD;
        -  Determine the pharmacokinetics of monoclonal antibody CAL in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, multicenter study. Patients are stratified&#xD;
      according to average prestudy pain score on question 3 of a daily electronic telephone pain&#xD;
      diary (less than 3 vs 3 or more) and prior bisphosphonate therapy (yes vs no). Patients are&#xD;
      randomized to 1 of 4 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive monoclonal antibody CAL IV over 30-60 minutes on day 1.&#xD;
&#xD;
        -  Arm II: Patients receive a lower dose of monoclonal antibody CAL as in arm I.&#xD;
&#xD;
        -  Arm III: Patients receive a lower dose (lower than arm II) of monoclonal antibody CAL as&#xD;
           in arm I.&#xD;
&#xD;
        -  Arm IV: Patients receive zoledronate IV over 30-60 minutes on day 1. Treatment in all&#xD;
           arms repeats every 28 days for 6 courses in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      Patients keep a pain diary throughout study participation.&#xD;
&#xD;
      Patients are followed at 24 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 72 patients (18 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <condition>Hypercalcemia of Malignancy</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Pain</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>monoclonal antibody CAL</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zoledronic acid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed breast cancer&#xD;
&#xD;
          -  Radiographical evidence of at least 1 bone metastasis&#xD;
&#xD;
               -  No prior radiotherapy or surgery to bone metastasis&#xD;
&#xD;
               -  No radiotherapy or surgery anticipated for bone metastasis within the next 24&#xD;
                  weeks&#xD;
&#xD;
          -  Bone pain severity score of at least 1 on 5 of 7 days as determined by question 3 of&#xD;
             the Brief Pain Inventory (BPI)&#xD;
&#xD;
          -  No bone metastases to a weight-bearing bone at imminent risk for pathologic fracture&#xD;
             or surgical intervention&#xD;
&#xD;
          -  No vertebral metastases that place the patient at imminent risk of spinal cord&#xD;
             compression&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Pre- or post-menopausal&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 2,000/mm^3&#xD;
&#xD;
          -  Lymphocyte count at least 500/mm^3&#xD;
&#xD;
          -  Granulocyte count at least 1,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 50,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  ALT or AST no greater than 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Calcium no greater than 10.1 mg/dL&#xD;
&#xD;
          -  No oliguria, defined as less than 30 mL urine per 2-hour collection&#xD;
&#xD;
          -  No acute renal failure&#xD;
&#xD;
          -  Creatinine no greater than 2.5 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
          -  No sepsis&#xD;
&#xD;
          -  No known or anticipated contraindication to study drugs&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 3 weeks since initiation of a new chemotherapy regimen&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 3 weeks since initiation of a new hormonal therapy regimen&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 3 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 60 days since prior bisphosphonates&#xD;
&#xD;
          -  More than 30 days since prior investigational drugs&#xD;
&#xD;
          -  No change in analgesic drug regimen during the screening period&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula Silverman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>May 6, 2003</study_first_submitted>
  <study_first_submitted_qc>May 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2003</study_first_posted>
  <last_update_submitted>May 13, 2013</last_update_submitted>
  <last_update_submitted_qc>May 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2013</last_update_posted>
  <keyword>hypercalcemia of malignancy</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>bone metastases</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hypercalcemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

